The Next Frontier of Medicine: Tevogen Bio ($TVGN)

Tevogen Bio's Dr. Neal Flomenberg, Chief Scientific Officer, and Dr. Lori Grosso, Clinical Development Lead, sit down with Nasdaq's Kristina Ayanian to discuss how the clinical-stage specialty immunotherapy company is harnessing CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Format

YouTube

Source

Tevogen Bio Inc